Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

• Viktor Grünwald,
• Thomas Powles,
• Masatoshi Eto,
• Evgeny Kopyltsov,
• Sun Young Rha,
• Camillo Porta,
• Robert Motzer,
• Thomas E. Hutson,
• María José Méndez-Vidal,
• Sung-Hoo Hong,
• Eric Winquist,
• Jeffrey C. Goh,
• Pablo Maroto,
• Tomas Buchler,
• Toshio Takagi,
• Joseph E. Burgents,
• Rodolfo Perini,
• Cixin He,
• Chinyere E. Okpara,
• Jodi McKenzie,
• Toni K. Choueiri

Affiliations

Viktor Grünwald

Clinic for Medical Oncology and Clinic for Urology, University Hospital Essen, Essen, Germany

Thomas Powles

Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, United Kingdom

Masatoshi Eto

Department of Urology, Kyushu University, Fukuoka, Japan

Evgeny Kopyltsov

State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia

Sun Young Rha

Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea

Camillo Porta

Department of Biomedical Sciences and Human Oncology, University of Bari ‘A. Moro’, Bari, Italy

Robert Motzer

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States

Thomas E. Hutson

Medical Oncology, Texas Oncology, Dallas, TX, United States

María José Méndez-Vidal

Department of Oncology, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) Hospital Universitario Reina Sofía, Córdoba, Spain

Sung-Hoo Hong

0Department of Urology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea

Eric Winquist

1Department of Oncology, University of Western Ontario, London, ON, Canada

Jeffrey C. Goh

2ICON Research, South Brisbane & University of Queensland, St Lucia, QLD, Australia

Pablo Maroto

3Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Tomas Buchler

4Department of Oncology, Charles University and Thomayer University Hospital, Prague, Czechia

Toshio Takagi

5Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan

Joseph E. Burgents

6Global Clinical Development, Merck & Co., Inc., Rahway, NJ, United States

Rodolfo Perini

7Clinical Research, Merck & Co., Inc., Rahway, NJ, United States

Cixin He

8Biostatistics, Eisai Inc., Nutley, NJ, United States

Chinyere E. Okpara

9Clinical Research, Eisai Ltd., Hatfield, United Kingdom

Jodi McKenzie

0Clinical Research, Eisai Inc., Nutley, NJ, United States

Toni K. Choueiri

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States